Characteristics of CBFB/MYH11-rearranged patients
| Variable . | FLT3 N676 wt . | FLT3 N676K mut . | P . | ||
|---|---|---|---|---|---|
| No. . | % . | No. . | % . | ||
| No. of patients | 51 | 5 | |||
| Age, years | N/S | ||||
| Median | 42 | 54 | |||
| Range | 20-75 | 18-61 | |||
| Male sex | 22 | 43.1 | 5 | 100 | .02 |
| White blood cells × 109/L | .02 | ||||
| Median | 38.5 | 134 | |||
| Range | 1.3-316 | 54.1-259 | |||
| Hemoglobin, g/dL | N/S | ||||
| Median | 8.6 | 9.1 | |||
| Range | 4.4-14.6 | 8-14.1 | |||
| Platelets × 109/L | N/S | ||||
| Median | 32 | 44 | |||
| Range | 0.01-370 | 32-47 | |||
| LDH (U/L) | .02 | ||||
| Median | 666 | 1326 | |||
| Range | 143-1870 | 717-2508 | |||
| Bone marrow blasts (%) | N/S | ||||
| Median | 80 | 60 | |||
| Range | 25-95 | 10-90 | |||
| ECOG performance status ≥ 2 (%) | 14 | 29.2 | 1 | 20 | N/S |
| de novo AML | 46 | 90.2 | 3 | 75 | N/S |
| NPM1 mut | 0 | 0 | 0 | 0 | N/S |
| FLT3-ITD | 2 | 3.9 | 0 | 0 | N/S |
| FLT3-D835 | 5 | 9.8 | 0 | 0 | N/S |
| MLL-PTD | 1 | 2 | 0 | 0 | N/S |
| KRAS mut | 7 | 13.7 | 0 | 0 | N/S |
| NRAS mut | 21 | 41.2 | 0 | 0 | .15 |
| KIT mut | 10 | 19.6 | 0 | 0 | N/S |
| WT1 mut | 4 | 7.8 | 0 | 0 | N/S |
| Complete remission | 39 | 76 | 2 | 40 | .11 |
| Deceased | 19 | 37.2 | 2 | 40 | N/S |
| Variable . | FLT3 N676 wt . | FLT3 N676K mut . | P . | ||
|---|---|---|---|---|---|
| No. . | % . | No. . | % . | ||
| No. of patients | 51 | 5 | |||
| Age, years | N/S | ||||
| Median | 42 | 54 | |||
| Range | 20-75 | 18-61 | |||
| Male sex | 22 | 43.1 | 5 | 100 | .02 |
| White blood cells × 109/L | .02 | ||||
| Median | 38.5 | 134 | |||
| Range | 1.3-316 | 54.1-259 | |||
| Hemoglobin, g/dL | N/S | ||||
| Median | 8.6 | 9.1 | |||
| Range | 4.4-14.6 | 8-14.1 | |||
| Platelets × 109/L | N/S | ||||
| Median | 32 | 44 | |||
| Range | 0.01-370 | 32-47 | |||
| LDH (U/L) | .02 | ||||
| Median | 666 | 1326 | |||
| Range | 143-1870 | 717-2508 | |||
| Bone marrow blasts (%) | N/S | ||||
| Median | 80 | 60 | |||
| Range | 25-95 | 10-90 | |||
| ECOG performance status ≥ 2 (%) | 14 | 29.2 | 1 | 20 | N/S |
| de novo AML | 46 | 90.2 | 3 | 75 | N/S |
| NPM1 mut | 0 | 0 | 0 | 0 | N/S |
| FLT3-ITD | 2 | 3.9 | 0 | 0 | N/S |
| FLT3-D835 | 5 | 9.8 | 0 | 0 | N/S |
| MLL-PTD | 1 | 2 | 0 | 0 | N/S |
| KRAS mut | 7 | 13.7 | 0 | 0 | N/S |
| NRAS mut | 21 | 41.2 | 0 | 0 | .15 |
| KIT mut | 10 | 19.6 | 0 | 0 | N/S |
| WT1 mut | 4 | 7.8 | 0 | 0 | N/S |
| Complete remission | 39 | 76 | 2 | 40 | .11 |
| Deceased | 19 | 37.2 | 2 | 40 | N/S |
All patients were enrolled in the AMLCG-99 trial and received intensive induction treatment. Categorical clinical variables of the FLT3 N676K-mutated (mut) and FLT3 N676 wild-type (wt) cohorts were compared by Fisher’s exact test. The continuous variables were compared by Mann-Whitney U test. P < .05 was considered significant. ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase.